Sprycel

This page shows the latest Sprycel news and features for those working in and with pharma, biotech and healthcare.

BMS’ Opdivo stalls in Q3, but overall figures still top expectations

and leukaemia drug Sprycel (dasatinib) which brought in $558m, also up 14%.

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

There were also new indications approved for UCB’s Cimzia (certolizumab pegol), Amgen’s Prolia (denosumab), BMS’ Sprycel (dasatinib) and Yervoy (ipilimumab), Pfizer’s Xeljanz (tofacitinib), and Novo Nordisk’s Xultophy
NICE backs BMS leukaemia drug Sprycel

Overturning its former ruling against the oral therapy, NICE recommended Sprycel in final guidance for first- and second-line treatment of adults with CML. ... BMS has now agreed a patient access scheme for Sprycel, which brought in sales of $472m this
Opdivo drives gain in BMS sales, but business revamp coming

BMS' other growth products also contributed to the sales gains, with melanoma drug Yervoy (ipilimumab) rising 19% to $285m and Sprycel (dasatinib) for leukaemia up 15% to $472m.
Pharma condemns Cancer Drugs Fund cuts

Bristol-Myers Squibb. Sprycel (dasatinib). Chronic myeloid leukaemia. Eisai. Halaven (eribulin). Breast cancer.
NHS names drugs to be re-evaluated for Cancer Drugs Fund

Company. Drug. Indication. Bayer. Stivarga (regorafenib). Sarcoma. Bristol-Myers Squibb. Sprycel (dasatinib).

More from news
Approximately 4 fully matching, plus 26 partially matching documents found.

Interview: Harvey Berger and Timothy Clackson, Ariad

recommended for use in patients who have grown resistance to Tasigna (nilotinib) and Gleevec/Glivec (imatinib mesylate) from Novartis and Bristol-Myers Squibb's Sprycel (dasatinib). ... The drug was then developed with the specific intention of
Intellectual property threats in the BRIC markets

of the compulsory licence process for Herceptin, Sprycel and Ixempra, revocation of a patent for Pfizer's Sutent and a legal ruling allowing a generic version of Tarceva.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Add my company

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Are you ready for the digital health revolution?: In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?: Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
Empowering patients empowers results: Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...